Oncopeptides AB (publ) (STO: ONCO)
Sweden
· Delayed Price · Currency is SEK 1.536
+0.026 (1.72%)
Nov 22, 2024, 5:29 PM CET
Oncopeptides AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 27.07 | 35.22 | 8.36 | 118.3 | - | - | Upgrade
|
| Revenue Growth (YoY) | -11.08% | 321.54% | -92.94% | - | - | - | Upgrade
|
| Cost of Revenue | 2.72 | -1.08 | 0.01 | 53.12 | - | - | Upgrade
|
| Gross Profit | 24.35 | 36.3 | 8.35 | 65.17 | - | - | Upgrade
|
| Selling, General & Admin | 197.1 | 188.48 | 142.2 | 873.81 | 654.19 | 199.46 | Upgrade
|
| Research & Development | 111.11 | 106.95 | 217.66 | 679.93 | 866.21 | 548.27 | Upgrade
|
| Other Operating Expenses | -3.37 | -6.34 | -4.57 | 3.9 | - | - | Upgrade
|
| Operating Expenses | 304.84 | 289.09 | 355.29 | 1,558 | 1,520 | 747.73 | Upgrade
|
| Operating Income | -280.49 | -252.79 | -346.94 | -1,492 | -1,520 | -747.73 | Upgrade
|
| Interest Expense | -7.19 | -5.79 | -0.88 | -0.95 | -1.49 | -0.53 | Upgrade
|
| Interest & Investment Income | 5.44 | 8.59 | 2.62 | 0.49 | 0.32 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 1.54 | 1.54 | 8.96 | 71.54 | -70.87 | 8.34 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | - | - | 0 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -280.7 | -248.45 | -336.24 | -1,421 | -1,592 | -739.92 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -1.44 | - | - | - | Upgrade
|
| Pretax Income | -280.7 | -248.45 | -337.68 | -1,421 | -1,592 | -739.92 | Upgrade
|
| Income Tax Expense | 1.69 | 0.66 | 0.27 | 8.95 | 2.25 | 0.79 | Upgrade
|
| Net Income | -282.39 | -249.11 | -337.95 | -1,430 | -1,595 | -740.71 | Upgrade
|
| Net Income to Common | -282.39 | -249.11 | -337.95 | -1,430 | -1,595 | -740.71 | Upgrade
|
| Shares Outstanding (Basic) | 136 | 90 | 82 | 75 | 62 | 52 | Upgrade
|
| Shares Outstanding (Diluted) | 136 | 90 | 82 | 75 | 62 | 52 | Upgrade
|
| Shares Change (YoY) | 50.76% | 9.80% | 9.33% | 20.72% | 20.63% | 20.43% | Upgrade
|
| EPS (Basic) | -2.07 | -2.76 | -4.11 | -19.00 | -25.57 | -14.33 | Upgrade
|
| EPS (Diluted) | -2.07 | -2.76 | -4.11 | -19.00 | -25.57 | -14.33 | Upgrade
|
| Free Cash Flow | -244.58 | -279.61 | -423.02 | -1,517 | -1,314 | -691.08 | Upgrade
|
| Free Cash Flow Per Share | -1.80 | -3.09 | -5.14 | -20.14 | -21.06 | -13.37 | Upgrade
|
| Gross Margin | 89.96% | 103.06% | 99.93% | 55.09% | - | - | Upgrade
|
| Operating Margin | -1036.11% | -717.74% | -4152.44% | -1261.64% | - | - | Upgrade
|
| Profit Margin | -1043.15% | -707.30% | -4044.90% | -1209.11% | - | - | Upgrade
|
| Free Cash Flow Margin | -903.49% | -793.89% | -5063.03% | -1282.16% | - | - | Upgrade
|
| EBITDA | -277.72 | -250.35 | -344.93 | -1,491 | -1,519 | -747.35 | Upgrade
|
| D&A For EBITDA | 2.76 | 2.44 | 2.01 | 1.72 | 1.72 | 0.38 | Upgrade
|
| EBIT | -280.49 | -252.79 | -346.94 | -1,492 | -1,520 | -747.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.